Medtronic (MDT 2.62%) stock was a fairly hot item as the trading week kicked off, with investors pushing the shares up by almost 3% in value. They liked the medical device specialist's latest piece of news about one of its products, and reacted accordingly. The stock's gain easily topped that of the S&P 500 (^GSPC 0.55%), which closed the day up 0.6%. A viable alternative to surgery More encouragingly, those using Medtronic's device demonstrated superior valve performance across the five- year period. Medtr ...

NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. "We remain highly focused on execution of the BACKBEAT global pivotal study, which we believe has the potential to deliver landmark results that can estab ...

Healthcare can be a complex sector, and it is one that I long ago decided to outsource to the industry professionals who run closed-end fund Blackrock Health Sciences Trust. But I couldn't resist dipping my toe into the sector when I saw the historically high yield on offer from Medtronic (MDT -0.21%), one of the largest and most diversified medical device makers.Here's why this is the one healthcare stock I own and why I think it will help set me up for life -- and may do the same for you too if you buy it ...

The broader market rally, which pushed the benchmark to a two-week record high yesterday, fueled by tech giants like NVIDIA and Tesla, has provided a much-needed breather for investors. This has potentially set the stage for stocks like Medtronic (MDT) to gain momentum.Over the past couple of months, Medtronic’s stock performance has remained sluggish, declining by 0.8%, reflecting the broader industry trend amid challenges such as aggressive tariff policies, trade tensions, and inflationary pressures. Duri ...

For Immediate ReleasesChicago, IL – March 25, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Boston Scientific (BSX) , Abbott (ABT) and Medtronic (MDT) .Here are highlights from Tuesday’s Analyst Blog:Amid Stagnation Fears, Boston Scientific Is a Buy on Growth FactorsBoston Scientific is experiencing a temporary ...

It has been about a month since the last earnings report for Medtronic (MDT) . Shares have added about 5.6% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Medtronic due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.How Have Estimates Been Moving Since Then?It turns ...

Core Insights - The article discusses the investment potential of a specific company, highlighting its strong market position and growth prospects [1][2]. Company Analysis - The company has demonstrated a beneficial long position in its shares, indicating confidence in its future performance [1]. - The analysis emphasizes the company's financial health and strategic initiatives that could drive future growth [1]. Industry Context - The broader industry trends are favorable, with increasing demand for the company's products and services, positioning it well for future expansion [1]. - Competitive landscape analysis suggests that the company is well-positioned against its peers, leveraging its strengths to capture market share [1].

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? The ...

Medtronic plc (MDT) recently unveiled two-year Small Annuli Randomized to Evolut or SAPIEN (“SMART”) Trial results at the Cardiovascular Research Technologies (“CRT”) 2025 conference in Washington, D.C. SMART trial is the largest international head-to-head comparative trial of transfemoral transcatheter aortic valve replacement ("TAVR"), conducted in patients with aortic stenosis ("AS") and a small aortic annulus. The two-year results highlighted the continued superior performance of the Evolut TAVR valve i ...

Core Insights - The SMART Trial presents the two-year results of the largest international head-to-head randomized control trial comparing Evolut and SAPIEN TAVR devices, primarily enrolling women with small aortic annuli [1][3][4] - Evolut TAVR demonstrated superior valve performance and significantly less bioprosthetic valve dysfunction (BVD) compared to SAPIEN TAVR, which is critical for patients with small aortic annuli [2][4][6] Company Overview - Medtronic plc is a global leader in healthcare technology, headquartered in Galway, Ireland, with a mission to alleviate pain, restore health, and extend life [6] - The company employs over 95,000 people across 150 countries, focusing on innovative technologies that address challenging health problems [6][7] Industry Context - Aortic stenosis affects approximately 1.5 million people in the U.S., with a significant portion of the global market having small aortic annuli, necessitating tailored valve selection [5] - The SMART Trial's findings are expected to inform and personalize treatment decisions for patients with symptomatic severe aortic stenosis [2][4]